Skip to main content
Navigate Up
Sign In

New Drug Repurposing Resource from CTSA Program

New Drug Repurposing Resource (ReFrame) Available from Scripps Research Institute CTSA

Dear CCTSI Members:

The Scripps Research Institute CTSA is making available to other CTSA hubs (including the CCTSI) a new drug repurposing resource called “ReFrame”, which is a 12,000+ compound library comprising drugs that have been evaluated in clinical development or approved for use. Compounds identified from screening this library are nearly all appropriate for immediate testing in animals and in many cases could be directly repurposed in new disease indications. 

CCTSI-affiliated researchers and clinicians who have identified potential drug targets, pathways or screening approaches--and are interested in accelerated translation into patients through drug repurposing--are encouraged to respond to a call for proposals​ that Scripps has posted, which also contains relevant background information on the project.

Scripps’ CTSA has a small budget allocated to help support screening efforts and make compounds available to collaborators, and they are enthusiastic to apply together for supplemental funding (both under the CTSA umbrella and elsewhere) if initial screening yields exciting results.

In addition I wanted to call your attention to our own local Drug Screening Program at the AMC:

Integrated Drug Discovery Cores at Anschutz Medical Campus​. Integrated drug discovery cores for the AMC campus are located in the School of Pharmacy. Cores are provided in Computational Chemistry and Biology (contact Philip Reigan), High Throughput/High Content Screening (contact Daniel LaBarbera), and Medicinal Chemistry​ (contact Michael Wempe). These cores  provide opportunities for in-silico screening of compounds against potential targets, high throughput screening using chemical libraries with high content imaging in either 2D or 3D cultures, and chemical synthesis of molecules of interest and/or metabolite characterization If you are unsure of who to contact, general advice can be provided by David Ross.

Please let us know if the CCTSI can be of any assistance in accessing these important resources.

All the best,

Ronald J. Sokol, MD, FAASLD
Director, CCTSI
Assistant Vice Chancellor for Clinical and Translational Science
University of Colorado Denver​

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.